Payment overview · 2025
General Payments
$408.56
13 reported records · 6 companies
Healthcare provider profile · identity verified
Warren Geisler, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1902867955
Verified facts
What the public records show
CMS Open Payments records show Warren Geisler, M.D. received $408.56 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $136.82 | 33.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.06 | 25.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.00 | 15.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.74 | 12.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.98 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.96 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.56 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.06 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $102.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.00 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.00 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 153 |
| Losartan Potassium | Losartan Potassium | 302 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 75 |
| Metformin Hcl | Metformin Hcl | 254 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 82 |
| Simvastatin | Simvastatin | 205 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 58 |
| Omeprazole | Omeprazole | 192 | 65 |
| Furosemide | Furosemide | 174 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | suppressed |
| Diazepam | Diazepam | 100 | 16 |
| Jardiance | Empagliflozin | 99 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 30 |
| Alprazolam | Alprazolam | 93 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 29 |
| Eliquis | Apixaban | 90 | 20 |
| Lisinopril | Lisinopril | 84 | 31 |
| Gabapentin | Gabapentin | 71 | 18 |
| Azithromycin | Azithromycin | 70 | 43 |
| Cefuroxime | Cefuroxime Axetil | 67 | 46 |
| Ozempic | Semaglutide | 63 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 18 |
| Sertraline Hcl | Sertraline Hcl | 58 | 21 |
| Tramadol Hcl | Tramadol Hcl | 57 | 11 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Atenolol | Atenolol | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Allopurinol | Allopurinol | 42 | 12 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Famotidine | Famotidine | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 15 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Prednisone | Prednisone | 32 | 14 |
| Ramipril | Ramipril | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 15 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.56 · 13 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE, NURTEC ODT, Ozempic, The Cologuard Plus Collection Kit, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error